1.20

1.64% -0.02

Cytosorbents Corp (CTSO)

Overview News Price History Option Chain Financials Why CTSO Down? Discussions Forecast Stock Split

Cytosorbents Corp stock is traded at $1.20, with a volume of 75,233. It is down -1.64% in the last 24 hours and up +33.33% over the past month. CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Previous Close:

$1.22

Open:

$1.21

24h Volume:

75,233

Relative Volume:

0.77

Market Cap:

$66.37M

Revenue:

$33.79M

Net Income/Loss:

$-18.67M

P/E Ratio:

-3.3501

EPS:

-0.3582

Net Cash Flow:

$-19.17M

1W Performance:

+13.21%

1M Performance:

+33.33%

6M Performance:

+48.13%

1Y Performance:

+44.21%

1-Day Range:

$1.15

$1.25

1-Week Range:

$1.03

$1.29

52-Week Range:

$0.70

$1.61

Cytosorbents Corp Stock (CTSO) Company Profile

Name

Cytosorbents Corp

Sector

Healthcare (1172)

Industry

Medical Devices (150)

Phone

973-329-8885

Address

305 COLLEGE ROAD EAST, PRINCETON, NJ

Employee

149

Twitter

@CytoSorbents

Next Earnings Date

2025-03-31

Latest SEC Filings

CTSO's Discussions on Twitter

Compare CTSO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTSO Cytosorbents Corp	1.20	66.37M	33.79M	-18.67M	-19.17M	-0.3582
ABT Abbott Laboratories	132.28	233.36B	42.34B	13.50B	6.66B	7.71
SYK Stryker Corp	373.37	147.15B	23.22B	2.86B	3.58B	7.40
BSX Boston Scientific Corp	101.73	146.97B	17.55B	2.03B	2.72B	1.37
MDT Medtronic Plc	86.17	112.76B	33.54B	4.66B	5.19B	3.62
EW Edwards Lifesciences Corp	73.27	44.46B	5.54B	4.18B	623.10M	7.00

Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-07-23	Initiated	B. Riley Securities	Buy
Oct-14-21	Resumed	B. Riley Securities	Buy
Sep-17-20	Initiated	Jefferies	Buy
Sep-01-20	Initiated	SVB Leerink	Outperform
Aug-08-17	Reiterated	Maxim Group	Buy
Oct-26-16	Initiated	Aegis Capital	Buy
May-24-16	Initiated	Maxim Group	Buy
Oct-29-15	Upgrade	WBB Securities	Speculative Buy → Buy
May-12-15	Reiterated	MLV & Co	Buy
Apr-01-15	Reiterated	MLV & Co	Buy
Mar-05-15	Initiated	MLV & Co	Buy
Feb-25-15	Initiated	WBB Securities	Speculative Buy
Jan-27-15	Reiterated	H.C. Wainwright	Buy

View All

Cytosorbents Corp Stock (CTSO) Latest News

Jun 15, 2025

Millennium Management LLC Buys Shares of 33,280 Cytosorbents Co. (NASDAQ:CTSO) - Defense World

Jun 15, 2025

Jun 13, 2025

Cytosorbents announces voting results from annual meeting By Investing.com - Investing.com Canada

Jun 13, 2025

Cytosorbents announces voting results from annual meeting - Investing.com

Jun 13, 2025

Jun 11, 2025

CytoSorbents Warrants Expire Worthless as Stock Price Fails Threshold - Investing.com

Jun 11, 2025

Jun 04, 2025

Cytosorbents Co. (NASDAQ:CTSO) Shares Purchased by Northern Trust Corp - Defense World

Jun 04, 2025

May 29, 2025

Critical Care Leader CytoSorbents Reveals Growth Strategy at Jefferies Healthcare Conference - Stock Titan

May 29, 2025

May 22, 2025

Cytosorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented At EuroPCR 2025 - marketscreener.com

May 22, 2025

CytoSorbents device cuts bleeding in CABG patients - Investing.com

May 22, 2025

New Clinical Data: How CytoSorbents' Breakthrough Device Slashes Severe Bleeding Risk in Urgent Heart Surgery - Stock Titan

May 22, 2025

May 21, 2025

Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - Defense World

May 21, 2025

May 19, 2025

Cytosorbents FY2025 EPS Forecast Lifted by HC Wainwright - Defense World

May 19, 2025

May 17, 2025

D. Boral Capital Reiterates “Buy” Rating for Cytosorbents (NASDAQ:CTSO) - Defense World

May 17, 2025

Cytosorbents (NASDAQ:CTSO) Earns Neutral Rating from HC Wainwright - Defense World

May 17, 2025

May 16, 2025

Cytosorbents Corporation (NASDAQ:CTSO) Q1 2025 Earnings Call Transcript - Insider Monkey

May 16, 2025

May 15, 2025

Cytosorbents Corp’s Earnings Call: A Balanced Outlook - TipRanks

May 15, 2025

CytoSorbents (CTSO) Receives Neutral Rating from HC Wainwright & Co. | CTSO Stock News - GuruFocus

May 15, 2025

CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | - GuruFocus

May 15, 2025

CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | CTSO Stock News - GuruFocus

May 15, 2025

CytoSorbents: Q1 Earnings Snapshot - CT Insider

May 15, 2025